Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Metformin, the popular type 2 diabetes medication, may be an effective AFib treatment

A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.

Cardiologist says COVID-19 vaccinations ‘must stop’ due to the risk of adverse events—scientists and doctors push back

A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond.

A FEOPS image of a Watchman LAA occluder device being checked for virtual sizing in an anatomical model of the patient's left atrial appendage. Dhanunjaya Lakkireddy, MD, explains the role and technology of LAA closure devices in managing AFib patients.

VIDEO: The value of left atrial appendage occlusion in AFib patients

Dhanunjaya Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, explains recent trials in left atrial appendage occlusion (LAAO) and how the therapy helps atrial fibrillation (AFib) patients.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA grants fast track designation to tirzepatide, Eli Lilly’s new type 2 diabetes drug, for treating obesity

Back in May, tirzepatide was approved by the FDA for improving glycemic control among adults with type 2 diabetes.

P2Y12 inhibitor monotherapy after PCI similar to prolonged DAPT, new 3-year analysis confirms

Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years.

FDA recall. The medications involved are atenolol, which treats hypertension, and clopidogrel, which reduces the risk of an acute myocardial infarction (AMI) or stroke among patients with a history of AMI, severe chest pain or circulation problems.

FDA announces recall of 2 cardiovascular medications due to labeling mix-up

Patients face a risk of adverse events if they mistakenly take the wrong medication, according to a new warning from the FDA.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

birth control the pill cardiovascular disease blood clots side effects

Blood clots much more common among obese women taking combination birth control pills

Progestin-only products may be a "safer alternative" for this patient population, according to a new analysis.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes